	US 12,221,642 B2
	Modified bacterial protein expression system
Maxwell Gottesman, New York, NY (US)
Assigned to University in the City of New York, New York, NY (US)
Filed by THE TRUSTESS OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US)
Filed on Feb. 3, 2023, as Appl. No. 18/105,587.
Application 18/105,587 is a division of application No. 16/886,156, filed on May 28, 2020, granted, now 11,624,081.
Application 16/886,156 is a division of application No. 15/764,070, granted, now 10,745,730, issued on May 28, 2020, previously published as PCT/US2016/054130, filed on Sep. 28, 2016.
Claims priority of provisional application 62/233,507, filed on Sep. 28, 2015.
Prior Publication US 2023/0304063 A1, Sep. 28, 2023
Int. Cl. C12N 9/00 (2006.01); C07K 14/245 (2006.01); C12N 9/52 (2006.01); C12N 15/10 (2006.01); C12N 15/70 (2006.01); C12P 21/02 (2006.01)

CPC C12P 21/02 (2013.01) [C07K 14/245 (2013.01); C12N 9/52 (2013.01); C12N 15/102 (2013.01); C12N 15/70 (2013.01)]

14 Claims

1. An engineered bacterium comprising at least one deficient protease, wherein the at least one protease is ClpQ (HslV), wherein the bacterium is engineered to disrupt and to express an exogenous peptide, wherein, prior to engineering, the bacterium is a protease deficient E. coli, wherein said protease deficient E. coli is deficient in a protease other than ClpQ (HslV), and wherein the engineered bacterium overexpresses the polypeptide at a level which is at least 2 fold greater compared to the level of the polypeptide produced by a bacterium not engineered with the deficient protease expressed by said E. coli prior to disruption of ClpQ (HslV), wherein said overexpression is induced at about 37° C.